Trial Profile
A Safety Surveillance Study of Events of Special Interest Occurring in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2021
Price :
$35
*
At a glance
- Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary)
- Indications Macular degeneration
- Focus Adverse reactions
- Sponsors Astellas Institute for Regenerative Medicine
- 24 Feb 2021 Planned End Date changed from 1 Dec 2029 to 31 Dec 2029.
- 24 Feb 2021 Planned primary completion date changed from 1 Dec 2029 to 31 Dec 2029.
- 06 Feb 2018 Planned number of patients changed from 37 to 36.